Isomorphic Labs announces strategic collaborations with two of the world’s leading pharmaceutical companies, Eli Lilly and Company and Novartis. These partnerships have the potential to be worth nearly $3 billion to Isomorphic Labs, excluding any royalties that may result from future drug sales, and are testament to Isomorphic’s approach to drug design and the progress we are making. Both collaborations are multi-target, focused on small molecules, and include a combination of upfront and milestone payments.
Read more in the news releases below.
Eli Lilly
Isomorphic Labs to Receive $45 Million in Upfront Payment For Multi-Target Research Collaborations with Lilly
